Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 272 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Warfarin Clear all
Terminated Phase 1 Interventional

Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

NCT00288808
View directory record Official record
Conditions
Blood Coagulation Disorder
Interventions
Hemosense (PT/InR point of care device)
Device
Lead sponsor
University of Rochester
Other
Eligibility
1 Day to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Sep 1, 2026, 10:45 AM EDT
Completed No phase listed Observational

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

NCT01825876
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, Warfarin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Clinical and Economic Implications of Genetic Testing for Warfarin Management

NCT00964353
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Warfarin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

Patent Foramen Ovale in Cryptogenic Stroke Study

NCT00697151
View directory record Official record
Conditions
Ischemic Stroke, Patent Foramen Ovale
Interventions
Warfarin, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Sep 1, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

NCT04593030
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
220,518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

NCT02617810
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Midazolam, Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

NCT00904176
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Warfarin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 1, 2026, 10:45 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
45
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

NCT02397382
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

NCT01432938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
dulaglutide, Warfarin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 1, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

NCT04593043
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Dabigatran
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
78,140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms Underlying Drug-Diet Interactions

NCT01034124
View directory record Official record
Conditions
Pharmacokinetics
Interventions
warfarin, vitamin K, midazolam
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340846
View directory record Official record
Conditions
Cancer
Interventions
Warfarin, Ketoconazole, Gemfibrozil, GSK2118436 150mg, GSK2118436 75mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 1, 2026, 10:45 AM EDT
Not listed No phase listed Observational

Study to Test the Accuracy of a Prototype Handheld PT/INR Device

NCT01349712
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
Universal Biosensors Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Batesville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 1, 2026, 10:45 AM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 1, 2026, 10:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 1, 2026, 10:45 AM EDT
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Cytochrome P450 4F Enzymes and Drug Interactions

NCT01250535
View directory record Official record
Conditions
Healthy Volunteers, Drug Drug Interactions
Interventions
Warfarin, Placebo, Lovastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938
View directory record Official record
Conditions
Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
Interventions
aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
54
States / cities
Tucson, Arizona • Santa Clara, California • West Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 1, 2026, 10:45 AM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 1, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Dalteparin sodium injection, Warfarin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 1, 2026, 10:45 AM EDT